Department of Gastroenterology, The First Affiliated Hospital of China Medical University, Shenyang 110001, Liaoning Province, China.
Department of Gastroenterology, Shengjing Hospital of China Medical University, Shenyang 110022, Liaoning Province, China.
World J Gastroenterol. 2024 Oct 21;30(39):4313-4317. doi: 10.3748/wjg.v30.i39.4313.
We comment on an article by Koizumi . Elafibranor (EFN) is a dual pero-xisome proliferator-activated receptor α/δ agonist. The experimental results from Koizumi demonstrated that EFN significantly increases intestinal barrier function and ameliorates liver fibrosis. These positive outcomes suggest that EFN could be a promising therapeutic option for alcohol-associated liver disease (ALD). However, this study has limitations that necessitate further research to evaluate the efficacy of EFN. Future studies should consider the use of more appropriate animal models and cell types, optimize the administration routes and dosages of the drug, and conduct an in-depth investigation into the underlying mechanisms of action to determine the therapeutic effects of EFN in humans. With sustained and in-depth research, EFN has the potential to emerge as a novel therapeutic agent for the treatment of ALD.
我们对 Koizumi 的一篇文章进行了评论。Elafibranor（EFN）是一种双重过氧化物酶体增殖物激活受体 α/δ 激动剂。Koizumi 的实验结果表明，EFN 可显著增加肠道屏障功能并改善肝纤维化。这些积极的结果表明，EFN 可能成为治疗酒精性肝病（ALD）的一种有前途的治疗选择。然而，这项研究存在局限性，需要进一步研究来评估 EFN 的疗效。未来的研究应考虑使用更合适的动物模型和细胞类型，优化药物的给药途径和剂量，并深入研究其作用机制，以确定 EFN 在人类中的治疗效果。通过持续深入的研究，EFN 有可能成为治疗 ALD 的一种新型治疗药物。
